OBJECTIVE: Confirmatory testing of suspected primary aldosteronism (PA) requires an extensive medication switch that can be difficult for patients with severe complicated hypertension and/or refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive medication on confirmatory testing results. To allow the results to be interpreted, the reproducibility of confirmatory testing was also evaluated. DESIGN AND METHODS: The study enrolled 114 individuals with suspected PA who underwent two confirmatory tests. The patients were divided into two groups. In Group A, both tests were performed on the guidelines-recommended therapy, i.e. not interfering with the renin-angiotensin-aldosterone system. In Group B, the first test was performed on chronic therapy with the exclusion of thiazides, loop diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion. RESULTS: Agreement in the interpretation of the two confirmatory tests was observed in 84 and 66% of patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum aldosterone levels ≥240 pmol/l, aldosterone was concordantly nonsuppressible during the other test. Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels ≥240 pmol/l on modified chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy. CONCLUSION: Confirmatory testing performed while the patient is on chronic therapy without diuretics and aldosterone antagonists can confirm the diagnosis of PA, provided serum aldosterone remains markedly elevated at the end of saline infusion.

Departments of Internal Medicine Nuclear Medicine Charles University Prague University Hospital Hradec Kralove Sokolska 581 Hradec Kralove Czech Republic

See more in PubMed

Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology. 2005;45:1243–1248. doi: 10.1016/j.jacc.2005.01.015. PubMed DOI

Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. Journal of the American Medical Association. 2006;295:2638–2645. doi: 10.1001/jama.295.22.2638. PubMed DOI

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2008;93:3266–3281. doi: 10.1210/jc.2008-0104. PubMed DOI

Ceral J, Malirova E, Kopecka P, Pelouch R, Solar M. The effect of oral sodium loading and saline infusion on direct active renin in healthy volunteers. Acta Endocrinologica. 2011;7:33–38. doi: 10.4183/aeb.2011.33. DOI

Solar M, Ceral J, Krajina A, Ballon M, Malirova E, Brodak M, Cap J. Adrenal venous sampling: where is the aldosterone disappearing to? Cardiovascular and Interventional Radiology. 2010;33:760–765. doi: 10.1007/s00270-009-9722-4. PubMed DOI PMC

Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism. 2006;91:2618–2623. doi: 10.1210/jc.2006-0078. PubMed DOI

Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF., Jr Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. Journal of Clinical Endocrinology and Metabolism. 2000;85:2854–2859. doi: 10.1210/jc.85.8.2854. PubMed DOI

Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. Journal of Renin–Angiotensin–Aldosterone System. 2001;2:156–169. doi: 10.3317/jraas.2001.022. PubMed DOI

Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension. 2007;50:424–431. doi: 10.1161/HYPERTENSIONAHA.107.091827. PubMed DOI

Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. European Journal of Endocrinology. 2006;154:865–873. doi: 10.1530/eje.1.02164. PubMed DOI

Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clinical Chemistry. 2006;52:1749–1755. doi: 10.1373/clinchem.2006.068502. PubMed DOI

Histopathological spectrum of common aldosterone-driver gene mutations in aldosterone-producing adenomas

Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production